Intradermal testing of intravenous anaesthetic drugs was performed on 34 patients following acute anaphylactoid reactions during anaesthesia. Twenty-three patients had positive skin tests and 18 of these were positive for a single drug. Muscle relaxants were the drugs implicated most commonly. Intradermal testing is safe and provides useful and often specific positive information, but falsenegative results probably occur.
Anaphylactoid reactions are hypersensitivity responses which are clinically indistinguishable from anaphylaxis, but without proven antibody involvement. I ,2 These reactions are a major cause of morbidity and mortality attributable to ~aesthesia. 3, 4 In 1977 there were three rep'--'orted deaths in New Zealand due to hypersensitivity to anaesthetic drugs,5 and in a five-year period, a large New Zealand metropolitan hospital admitted six patients to its Inten~ive Therapy Unit because of severe allergic reactions during anaesthesia. 6 There is no way of identifying the individual at risk for an anaphylactoid response although some groups of patients exhibit relative risk factors. v For the patient who has survived an anaphylactoid reaction during anaesthesia, it is essential to confirm the diagnosis and to identify the drug in order to avoid the same reaction in subsequent anaesthetics.
Although various components of the anaphylactic mechanism are measurable in man,2,8-13 the wheal and erythema skin response to allergen remains the basic tool for confirming IgE-mediated hypersensitivity. Although demonstrable IgE mediation (true anaphylaxis) probably does not occur in the majority of anaesthetic anaphylactoid reactions,8,14 drugs that have caused a reaction when given systemically also produce wheal and erythema when they are diluted and given intradermally. 1 The aim of this study was to assess the response to intradermal testing of anaesthetic drugs which had precipitated an anaphylactoid reaction when given intravenously.
Skin tests for allergy have earned a dubious reputation for reliability with some justification, particularly in the field of food allergy.15 Many of the defects can be overcome by standardising the testing procedure. 15 Such a protocol evolved from Currie 8 and Slavin l5 was devised by Fisher in 1976 for testing anaesthetic drugS. 16 The initial drug dilution (1:1000) and wheal diameter accepted as positive (15 mm) were selected empirically and have since required modification. 17 ,18,19 Fisher's testing procedure has evolved by comparing skin test responses with clinical events and confirming some positive results with the Prausnitz-Kustner (P-K) testS and Passive Cutaneous Anaphylaxis test (P .C.A.), a variant of the P-K test. 20 Both these tests demonstrate the presence of IgE specific to the antigen tested for. Fisher now suggests that the dilution for all induction agents should be 1: 100, for muscle relaxants 1: 1000 except d-tubocurarine (1: 10,000) and for narcotics other than fentanyl 1: 100,000. A wheal of 10 mm diameter or greater is accepted as positive if arising within ten minutes and persisting for at least 30 minutes. METHODS A skin testing service was offered for patients who had experienced hypersensitivity reactions to intravenous anaesthetic drugs. Anaesthetists throughout metropolitan Auckland were circularised. The referral form asked for details of the incident, its severity and the resuscitative measures used. A history of previous allergy, drug sensitivity or manifestation of atopy (asthma, eczema, hayfever) was also requested, together with details confirming the selection criteria set out below. Patient Selection Criteria 1. The patient had received intravenously one or more drugs associated with anaesthesia (not antibiotics or local anaesthetics).
The subsequent clinical events could
possibly have been an anaphylactoid response. 3. The clinical severity of the reaction was at least a measurable alteration in cardiovascular or respiratory function. 4. Where skin signs were the only disturbance, testing was performed only for induction agents given as sole agents. 5. The patient satisfied Fisher's original protocol: 16 (i) healthy, afebrile, non-dermographic, with intact nerve supply to ventral forearm (ii) no history of recent ingestion of drugs known to inhibit histamine release (iii) a period of at least four weeks elapsed since the reaction (iv) patients at the extremes of age excluded.
Testing Procedure
In the first 13 patients (Group A) Fisher's original protocol was followed:
1. Selection criteria had been met. 2. Solutions were injected into volunteer control subjects. 3. Injection technique: The anterior forearm was cleaned with alcohol. An intradermal injection of 0.1 ml was made using a 26 swg needle on a disposable 1.0 ml syringe. 4. Freshly prepared solution of the drug to be tested was diluted to 1: 1000 in normal saline. 5. A control injection of saline was made to exclude dermographia. 6. A positive result was a wheal of greater than 15 mm diameter persisting 30 minutes.
A smaller wheal was accepted as positive for Cremaphor-based drugs, if absent from controls. 7. Serial dilutions by a factor of 10 were used if more than one drug was positive. Two major modifications, based on published revisions of Fisher's protocol, 17, 18 were introduced in a further 21 patients (Group The severity of the anaphylactoid reactions was graded 1-4 according to the scale of Ring and Messmer 22 for quantitating plasmaexpander histamine mediated reactions (Table  1) . Cardiac arrest was defined as a clinically imperceptible circulation. 
RESULTS
Sixty-three patients were referred between September 1977 and December 1980. Twenty did not meet selection criteria, and of those who did, nine had pin-prick testing only. Intradermal skin testing was performed on the remaining 34 patients.
There were 27 females and seven males. Their average age was 35 years (range 12-70 years). Eleven subjects gave a history of previous allergy or atopic manifestation.
The majority of anaphylactoid reactions were life-threatening (70070 in Grade III or IV) which reflected the selection criteria. The distribution of severity is shown in Figure 1 . 
Intradermal Testing
In Group A using 1: 1 000 dilutions, no patient had a 15 mm or larger wheal. When a wheal of 10 mm diameter or more was accepted as positive seven of the 13 patients had a positive skin test ( Table 2 ). A single drug was positive in 18 cases, while in five cases, more than one agent was positive. Where more than one agent was positive, muscle relaxants were implicated on four occasions, and narcotics twice.
Other noteworthy features of testing were: 1. Six severe or very severe clinical reactions (grades III or IV) were associated with negative skin tests. 2. Althesin and thiopentone given as sole agents in cases number four, 20, 23, 30 produced only one positive skin test (althesin). Althesin given to case number four produced a negative skin test with the 1: 1000 dilution used. The other patients were tested with 1: 100 dilution. 3. The two althesin-positive cases (number 19, 20) were also positive to Cremophor EL. 4. Seven of the eight cases demonstrating urticaria at the time of the anaphylactoid reaction had positive skin tests. The exception was case number four. 5. An induction combination of thiopentone and suxamethonium produced anaphylactoid reactions in seven patients (numbers 6, 9, 24, 25, 26, 27, 29) ; four were positive for suxamethonium, two for thiopentone. 6. There were five positive reactions to induction agents and 21 positive reactions to muscle relaxants. Pancuronium or methohexitone had not been used in any of the patients referred. In Group B the mean wheal diameter after 0.01070 histamine IllJection was 18.0 mm. There were no complications from intradermal testing. DISCUSSION Clarke 3 considers that neither age nor sex alters the incidence of hypersensitivity reactions. Laforest and colleagues 7 reported 86 Australians who had reacted to anaesthetic drugs of whom 74070 were female.
A higher incidence of female referrals (79070) and of females with positive skin testing (78070) is also noted in this series. As in the study of Laforest, there is no obvious explanation for the higher proportion.
This study is in accord with Fisher's larger experience that skin testing is safe.
Reporting on intradermal testing in 51 patients, Fisher l ? had positive results in 32 (62070). This compares with 76% positive in comparable patients in this series (Group B). Fisher considered that false-positive results were unlikely because he had been able to "confirm" 26 of his 32 positive results. He regarded the result as confirmed if either:
(i) the drug used was the sole agent, or (ii) antibodies to the drug could be demonstrated by the P-K or P.C.A. tests, or (iii) the patient had, at a subsequent uneventful anaesthetic, received all the other drugs used when the reaction occurred. The only method for confirming negative results at the present time is direct challenge. 3 ,8,17 There is thus the possibility that some negative skin tests in this series are falsenegative.
The presence of urticaria in patient number four suggests that the result of subsequent skin testing using a 1: 1000 dilution of althesin was a false-negative. The result may have been positive using 1: 100 dilution.
In Group B, the clinical histories of the five patients with negative testing were re-examined. Only one was held to be unlikely to have had an anaphylactoid reaction. Fisher considered that over half of his 19 negative patients were in this category on clinical grounds. 17 It is difficult to interpret those cases in which a positive result was obtained with more than one agent. Fisher's original suggestion l6 was to test all the positive agents with serial dilutions by a factor of 10 to identify the drug responsible. This procedure was not adopted since it was believed that, if several drugs produced a significant skin histamine release on intradermal injection, then it was likely that they would do so if given in combination intravenously and thus they should all be avoided in future.
This view is to some extent supported by recent reports from Fisher l9 and Vervloet and colleagues 23 who described cross-sensitivity to muscle-relaxants in several individuals following anaphylactoid reactions to one relaxant. Fisher suggests that positive results for other relaxants which the individual has not previously received are not false-positive, but in Anaesthesia and Intensive Care. Vol. IX. No. 4, November, 1981 fact represent allergy to more than one agent. Lorenz questions the validity of skin testing with morphine and pethidine. 24 In this series muscle relaxants and morphine derivatives were implicated in the cases which produced positive wheals to more than one drug. CONCLUSION This study confirms the safety and simplicity of intradermal skin testing. When the procedure is performed as for the patients in Group B the test appears to provide useful information when positive. A negative intradermal test does not exclude the diagnosis of an anaphylactoid reaction even in a patient whose clinical history is doubtful. A patient who has an anaphylactoid reaction after receiving several agents intravenously and has a positive intradermal test to one of them should not be given that drug subsequently.
